News und Analysen

The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24^th Annual Meeting of the Society for Neuro-Oncology

The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies

The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases

Premier Inc. (NASDAQ: PINC), a healthcare improvement company, has formed a new organization that is focused on optimizing care through clinically led partnerships with large, national employers

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including:

• 
  Credit Suisse 28^th Annual Healthcare Conference

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 28^th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019, at approximately 10:20 a.m

VCU Health System, a comprehensive Level I trauma center verified in adult, pediatric and burn trauma care located in Richmond, Virginia, is collaborating with Premier Inc. (NASDAQ: PINC), a

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3

Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 first quarter ended Sept. 30, 2019.

All results presented in the following release reflect those of continuing

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 32-cents per share on the Company’s capital stock, payable on December 2, 2019